TrialBlood advances2022
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.
Amer M Zeidan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
59 papers cite it
this paperpooled ittrialcites it